"目錄號: HY-14188
Membrane Transporter/Ion ChannelAutophagy-
Amiodarone is a lipophilic antiarrhythmic/antianginal drug which is able to influence the physicochemical status of biological lipid components.
相關產品
Cycloheximide-TAK-242-LY294002-3-Methyladenine-(+)-JQ-1-SB 203580-SP600125-U0126-Enzalutamide-Actinomycin D-Olaparib-Doxorubicin hydrochloride-Dorsomorphin dihydrochloride-Mitomycin C-Bortezomib-
生物活性
Description
Amiodarone is an antiarrhythmic drug for inhibition of ATP-sensitive potassium channel with IC50 of 19.1 μM. IC50 Value: 1.5 uM ( inhibit TBARS, LOOH and FPL formation)[1]in vitro: It was found that 10 uM amiodarone induces accumulation of ethidium bromide (5 ug/ml) in Saccharomyces cerevisiae cells. At the same time, in yeast cells with inactivated MDR genes, accumulation of ethidium bromide was 6-fold higher even without amiodarone. Addition of non-lethal concentrations of amiodarone to MDR-deficient cells caused an increase of intracellular ethidium bromide to the level, which was even lower than the level in amiodarone-treated wild-type cells [2].? Cells treated with amiodarone were seen to have detached from the dish, with cell rounding, cytoplasmic blebbing and irregularity in shape. An increase in the sub-G1 phase fraction, from 15.43 to 21.34% and 79.83% and a reduction in the G1 phase fraction, from 48.83 to 41.63% and 11.52%, were observed in cells treated with amiodarone at concentrations of 0.1 and 1 mM, respectively [3].in vivo: Chronic treatment with oral amiodarone for 4 weeks reduced i.p. when myocytes were dialyzed with patch-pipettes containing either 10 mM Na+ or 80 mM Na+. In myocytes from untreated rabbits, acute exposure to amiodarone in vitro reduced i.p. when patch pipettes contained 10 mM Na+ but had no effect on i.p. at 80 mM Na+. Amiodarone had no effect on the voltage dependence of the pump or the affinity of the pump for extracellular K+ either after chronic treatment or during acute exposure [4].Clinical trial: Continuous Versus Episodic Amiodarone Treatment for the Prevention of Permanent Atrial Fibrillation . Phase not specified
Clinical Trial
University Medical Center Groningen
Persistent Atrial Fibrillation
August 2000
Phase 4
Population Health Research Institute-St. Jude Medical-Hamilton Health Sciences Corporation
Defibrillators, Implantable-Tachycardia, Ventricular
August 2010
Phase 3
University of Louisville
Atrial Fibrillation-Lung Transplant; Complications
August 1, 2017
Phase 2
Weill Medical College of Cornell University
Cardiac Disease
March 2012
The University of Texas Health Science Center at San Antonio
New Onset Atrial Fibrillation-Severe Sepsis-Septic Shock
May 2016
Phase 4
Western Galilee Hospital-Nahariya
Atrial Fibrillation
May 2013
Phase 3
Beth Israel Deaconess Medical Center
Atrial Fibrillation-Lung Cancer
February 2006
Phase 3
Aarhus University Hospital
Atrial Fibrillation
August 2008
Phase 4
Baystate Medical Center
Atrial Fibrillation
October 2011
Eastbourne General Hospital
Atrial Fibrillation
March 2011
Texas Cardiac Arrhythmia Research Foundation-University of Kansas-California Pacific Medical Center-Stanford University-Case Western Reserve University-Southlake Regional Health Centre-Catholic University, Italy
Atrial Fibrillation
October 2010
Phase 3
Fundación Cardioinfantil Instituto de Cardiología-Instituto de Corazón de Bucaramanga
Chagas Cardiomyopathy
June 12, 2017
Phase 3
Cardiome Pharma
Atrial Fibrillation
April 2008
Phase 3
St. Jude Medical
Atrial Fibrillation
July 2011
Sanofi
Atrial Fibrillation
June 2007
Phase 3
InCor Heart Institute-Ministry of Health, Brazil-St. Jude Medical-Funda??o de Amparo à Pesquisa do Estado de S?o Paulo
Chagas Cardiomyopathy-Non-sustained Ventricular Tachycardia-At Least 10 Points in Rassi Risk Score for Death
October 2014
Mayo Clinic
Other Intraoperative Cardiac Functional Disturbances During Cardiac Surgery
November 2007
Centre Hospitalier Universitaire, Amiens
Supraventricular Tachycardia
September 6, 2016
Phase 2
Emergency NGO Onlus
Ebola Virus Disease
December 2014
Phase 2-Phase 3
Kuopio University Hospital-Tampere University Hospital-Vaasa Central Hospital, Vaasa, Finland
Atrial Fibrillation-Cardiac Surgery
August 2007
Phase 4
Texas Cardiac Arrhythmia Research Foundation-Casa Sollievo della Sofferenza IRCCS-Catholic University, Italy-Southlake Regional Health Centre-Stanford University-University of Kansas-The University of Texas Medical Branch, Galveston-University of Foggia-Sutter Health
Heart Failure
October 2008
Phase 4
Memorial Sloan Kettering Cancer Center-Washington University School of Medicine-The Cleveland Clinic-Vanderbilt University School of Medicine
Thoracic Surgery-Atrial Fibrillation in High Risk Patients
April 2016
Phase 3
Cardiome Pharma
Atrial Fibrillation
September 2012
Phase 4
University Medical Center Groningen-Netherlands Heart Foundation
Persistant Atrial Fibrillation
January 2003
University of Washington-National Heart, Lung, and Blood Institute (NHLBI)-Canadian Institutes of Health Research (CIHR)-Heart and Stroke Foundation of Canada-American Heart Association-Defence Research and Development Canada-U.S. Army Medical Research and Materiel Command
Cardiac Arrest
May 2012
Phase 3
Prism Pharmaceuticals
Blood Pressure
August 2008
Phase 2
Guy Amit-Population Health Research Institute
Atrial Fibrillation
January 2016
Phase 4
Inova Health Care Services
Atrial Fibrillation
January 2011
Shiraz University of Medical Sciences
Atrial Fibrillation
March 2007
University of Calgary-Heart and Stroke Foundation of Canada-Wyeth is now a wholly owned subsidiary of Pfizer
Atrial Fibrillation
February 1999
Phase 3
Boehringer Ingelheim
Healthy
April 2006
Phase 1
Rigshospitalet, Denmark
Atrial Fibrillation
January 2009
Rambam Health Care Campus
Atrial Fibrillation
March 2016
Phase 3
Hospital General Universitario Gregorio Mara?on
Ventricular Tachycardia-Wide QRS Tachycardia
September 2005
Phase 4
Icahn School of Medicine at Mount Sinai-Biosense Webster, Inc.
Ventricular Tachycardia
October 2009
Sanofi
Arrhythmia Prophylaxis-Ventricular Arrhythmia
September 2009
Phase 2
Hartford Hospital-Gilead Sciences
Arrhythmia
February 2011
Indiana University-Purdue University-Indiana University Health
Atrial Fibrillation-Esophagectomy
September 2005
Phase 4
Charles University, Czech Republic
Supraventricular Arrhythmia-Septic Shock
February 2017
Phase 4
Centre Hospitalier Universitaire de Saint Etienne-Ministry of Health, France
Mitral Valvulopathy-Atrial Fibrillation
March 2012
Indiana University-Purdue University
Atrial Fibrillation
September 2004
Phase 4
VA Office of Research and Development
Atrial Fibrillation-Cerebrovascular Accident-Death, Sudden
April 1998
Phase 3
Ottawa Hospital Research Institute-Heart and Stroke Foundation of Ontario
Atrial Fibrillation
July 2007
Phase 4
Maine Medical Center
Atrial Fibrillation-Atrial Flutter
August 2009
Phase 3
Hunter Holmes Mcguire Veteran Affairs Medical Center-Virginia Commonwealth University-University of California, San Francisco-Univeristy of Calgary-University of Pittsburgh-Wake Forest University Health Sciences
Ventricular Premature Beats, Contractions, or Systoles-Cardiomyopathies
September 1, 2017
Phase 4
